Lupin receives USFDA approval for Phenylephrine and Ketorolac Intraocular Solution

Lupin receives USFDA approval for Phenylephrine and Ketorolac Intraocular Solution

Lupin Limited (Lupin) announced that it has received approval for its Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, from the United States Food and Drug Administration (U.S. FDA).

Lupin’s Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, is the generic version of Omidria Intraocular Solution, 1%/0.3%, Omeros Corporation (Omeros). It is indicated for:

• maintaining pupil size by preventing intraoperative miosis

• reducing postoperative ocular pain

Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement.

Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, had annual sales of approximately USD 42.8 million in the US (IQVIA MAT March 2019).